RankingsPricing
  1. US-listed companies
  2. Ultragenyx Pharmaceutical Inc.
  3. Raw

Ultragenyx Pharmaceutical Inc.RARE

Market cap
$3.1B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss-60-146-246-302-198-403-187-454-707-607-569
Stock-based compensation------86105130135158
Amortization of premium (discount) on marketable debt securities, net-4-6-5-236-1-7-31313
Depreciation and amortization11362091213182636
Change in fair value of equity investments-----13170-42-190-1
Non-cash collaboration royalty revenue------13182269101
Non-cash interest expense on liabilities for sales of future royalties-----13329436663
Other----0-1-1-00-23
Accounts receivable----820-105122334
Inventory----541310711
Prepaid expenses and other assets-----------12
Other assets----------15-
Accounts payable, accrued, and other liabilities-----13273287247
Deferred tax liabilities-----2---2-2-
Net cash used in operating activities-----291-345-132-339-380-475-414
Purchase of property, plant, and equipment251034254473116447
Acquisition, net of cash acquired---143----75--
Purchase of marketable debt securities------8131,012615526409
Proceeds from sale of marketable debt securities------519384513
Proceeds From Sale Of Equity Investment------808010--
Proceeds from maturities of marketable debt securities83249403274303676590718451696410
Payment for intangible asset--------30313
Other------61152
Net cash (used in) provided by investing activities-----33-13-179-195-292168-18
Proceeds from the sale of future royalties, net-----314--491--
Proceeds from the issuance of common stock and pre-funded warrants in connection with underwritten public offerings, net of issuance costs---------326381
Proceeds from the issuance of common stock in connection with at-the-market offering, net of issuances costs---------53-
Proceeds from the issuance of common stock from exercise of equity plan awards, net--892810894011811
Proceeds from Noncontrolling Interests----------7
Other-------0-0-1-0-
Net cash provided by financing activities----337679600119501388399
Effect of exchange rate changes on cash-----0-01-1-10-3
Net (decrease) increase in cash, cash equivalents, and restricted cash----12321290-417-17282-35
Acquired lease liabilities arising from obtaining right-of-use assets and property, plant, and equipment---------2210
Capital Expenditures Incurred but Not yet Paid-1001109191821
Non-cash interest expense on liability related to the sale of future royalties capitalized into ending property, plant and equipment-------5119-